P3781
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid DiseasePasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic MetastasesDocetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate CancerAn Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With AcromegalyA Study to Assess SOM230 in Patients With Pituitary Cushing's DiseaseStudy Evaluating SOM230 in Patients With Metastatic Carcinoid TumorsStudy Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic PatientsPasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialTrial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung CancerDose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast CancerSOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple MyelomaPasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate CancerIGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor EverolimusEvaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.Pasireotide LAR in Severe Polycystic Liver DiseaseHYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery ComplicationsStudy of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseImpact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections
P4844
Safety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I study.A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists.Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsSynergistic effect of pasireotide and teriflunomide in carcinoids in vitro.Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model.Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.Medical treatment of Cushing's disease.Effect of SOM230 (pasireotide) on corticotropic cells: action in dogs with Cushing's disease.Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells.Absence of somatostatin SST(2) receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model.Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.Involvement of bone morphogenetic protein activity in somatostatin actions on ovarian steroidogenesis.SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts.Pasireotide (SOM230) protects the retina in animal models of ischemia induced retinopathies.Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritisNovel therapeutic directions in Cushing's syndromeMedical Treatment with Somatostatin Analogues in Acromegaly: Position StatementTransient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndromeEffect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I studyStimulatory effect of SOM230 on human and rat adrenal corticosteroid secretion in vitro
P921
Q61924472-B2EC5ECD-138C-4E44-AB60-8BFF1DD58011Q61955769-D0C4058F-486B-4A5C-9EB5-76E6F4D5CCFBQ61955968-9A6E9E2F-E3F7-4AF7-A6A6-BCF7E037865BQ61969662-CB7F2219-8631-485B-924F-92C7A80B9946Q62110168-AA57CF23-4A8C-466D-ABDF-7C352EF0634CQ62110169-00C24B5F-0557-46C6-8137-F09299D360E4Q62110170-7B048F92-16D6-4856-BFD9-3214B1463E40Q62818645-EA32AC96-88AA-4EFC-9C71-FEC5D7CD7E8BQ63316021-8A869A66-6B6E-4D81-B055-68590A967C13Q63322745-4BE2C826-13E0-4A71-A8B9-C64A1251DEC3Q63334166-BE1D1608-5CE1-448E-A365-A9EF55A14BEDQ63336617-5ABC62F4-38E6-4393-AD14-6A0F0B079655Q63338327-F75AD3EE-2F14-42FA-8274-0E2B545A738CQ63338787-CE9B86B6-19AB-4777-854D-53C433C9C4D1Q63340788-240E54FE-9145-4A95-A7A8-F63A476DF3B6Q63572865-3C037345-0135-42AD-BBDC-3B818F3D1696Q63575839-803903BC-C961-441E-A6CA-C7DE253034B6Q63577874-B6D93676-1625-4D68-9DE7-2268351E4A46Q63590869-5DC5BA16-A9CC-431B-AB36-8A733EE5732BQ87930185-2AB93455-FF66-40AF-ADAE-EA9B558A4B46
P4844
Q33453558-4C1ED443-BC04-4DDC-B07E-E2CEE78A2E3BQ34321414-A356D868-CD18-4413-9994-4CA34BC7AAE2Q35001258-628A940A-BDEE-4989-BDB1-8D915EEC75EDQ35747137-6D4FF7F3-CECB-4AF6-8EB4-7251F61D7EF2Q36536629-51F70539-668F-4CBA-BDBA-ECC78F145FDFQ37066453-322192E6-0588-4653-A09E-266E83C4A1F3Q37898112-24B7710B-9F32-4FFE-8FEE-1D8A76C3CC6AQ37968553-3909205C-655D-4186-8241-101961E68EB7Q38076357-C495A3E6-9513-4DD6-B6B5-2EE1D45B122CQ39551743-D2548B10-DF0D-4BDB-9A52-294DE179ECEDQ39640805-9847864B-02D1-4E23-B05E-B51E5F0924F5Q39678436-F3C26F93-6BB4-4959-8219-E52E6B4B03A5Q39739369-060F0ED3-2FBC-424C-90E2-E6083BFEADB2Q42150896-A44D3EEE-B5C1-45DA-8911-0268AE1C5DEFQ42289652-AC1DDA66-DE49-4FF0-84A6-8C408306BD83Q42714373-7BF7D166-D584-457B-AE1B-AE2391216922Q43795921-8EF850E1-73EB-4440-8366-D02FAC5D3164Q48384174-2A6CEB34-11F2-43CE-A210-54C98D15725DQ48414772-F6FBE5AD-B430-4BF4-997C-DB01C29AAFFBQ51355360-C517877F-8B38-43FF-861F-C6062FF93D02Q60727886-1C4B0CA4-2DF8-41A5-956B-3E8A0AE6DB56Q64046953-DADCB719-44FB-4D8C-AEC9-86D6ED64BF49Q64064994-3113E794-62EF-4880-9242-228D0B235101Q83292193-67589A43-D358-4CDD-901F-B0A8DEB15C49Q83336615-DCE06A91-DFDE-44C9-9A9E-FADE7DCCAE90Q84226925-37F8A8E2-3BCF-4737-96EC-701635248E4D
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Pasireotid
@sh
Pasireotid
@sl
Pasireotid
@sr
Pasireotide
@en
Pasireotide
@it
Pasireotide
@nl
Pasireotide
@pt
Pasireotide
@vi
Pazireotid
@hu
pasiréotide
@fr
type
label
Pasireotid
@sh
Pasireotid
@sl
Pasireotid
@sr
Pasireotide
@en
Pasireotide
@it
Pasireotide
@nl
Pasireotide
@pt
Pasireotide
@vi
Pazireotid
@hu
pasiréotide
@fr
altLabel
Pasireotida
@en
Pasireotidum
@en
SOM 230
@en
SOM-230
@en
SOM230
@en
SOM230
@pt
Signifor
@pt
cyclo((4R)-4-(2-Aminoethylcarb ...... yl-L-tyrosyl-L- phenylalanyl-)
@en
prefLabel
Pasireotid
@sh
Pasireotid
@sl
Pasireotid
@sr
Pasireotide
@en
Pasireotide
@it
Pasireotide
@nl
Pasireotide
@pt
Pasireotide
@vi
Pazireotid
@hu
pasiréotide
@fr
P486
P592
P6366
P646
P661
P662
P665
P683
P1748
P2017
NCCCC[C@@H]1NC(=O)[C@@H](CC2=C ...... 6)NC1=O)OC(=O)NCCN)C8=CC=CC=C8
P2067
1,046.501424
P2115
N0000186784